Univest
Univest
  • Markets

Speciality Medicines (SPML) Share Price Falls 10.85% as SPML Slips to Rs 170

  • October 9, 2026
  • Posted by: Kunal Singla
  • Category: News
No Comments
Speciality Medicines Share Price
Speciality Medicines (SPML) share price fell to Rs 170 today, down 10.85% from the previous close. Market cap was Rs 165.13 crore.

Speciality Medicines Share Price moved lower on 09 October 2026, with SPML trading at Rs 170 after a 10.85% decline from the previous close of Rs 190.7. The company’s market capitalisation stood at Rs 165.13 crore, placing it in the Micro Cap category. According to Univest data, the price event is confirmed, but no company-specific catalyst is established. That makes the latest move primarily a price action story, not a news-led one.

The Speciality Medicines Share Price move is relevant because it came with the day’s low at Rs 169.95 and the day’s high matching the open at Rs 190.7. The stock therefore spent the day below its starting level, and SPML Stock News is being driven today by the numbers rather than a verified event trigger. According to latest Univest figures, investors tracking Speciality Medicines Share Price Today should first read the move alongside valuation, profitability and sector benchmarks.

Table of Contents

Toggle
  • Speciality Medicines (SPML) Share Price Today: Price Action Analysis
  • Speciality Medicines (SPML) Fundamental Analysis
  • Sector and Industry Context
  • Peer Comparison
  • Why Investors Are Watching Speciality Medicines
  • About Speciality Medicines
  • Track Speciality Medicines Share Price on Univest
  • Frequently Asked Questions
    • Why did Speciality Medicines Share Price fall today?
    • What is Speciality Medicines Share Price today?
    • Is Speciality Medicines a Micro Cap stock?
    • What does Speciality Medicines Share Price valuation show?
    • How strong are the profitability ratios for SPML?
    • What is the EPS and book value for Speciality Medicines Share Price?
    • Does Speciality Medicines pay a dividend?
    • How does SPML compare with Trading sector peers?
    • Should investors track Speciality Medicines Share Price on Univest?

Speciality Medicines (SPML) Share Price Today: Price Action Analysis

Metric Value
Current Price Rs 170
Previous Close Rs 190.7
Today's Move -Rs 20.70 (-10.85%)
Open Rs 190.7
High Rs 190.7
Low Rs 169.95
Market Capitalisation Rs 165.13 crore
Market Cap Category Micro Cap

Speciality Medicines Share Price Today showed a clear intraday decline. SPML opened at Rs 190.7, touched a high of Rs 190.7 and a low of Rs 169.95, before last trading at Rs 170. The fall of Rs 20.7 from the previous close translates into a 10.85% decline. In a Micro Cap company with Rs 165.13 crore market capitalisation, that is a sizeable one-day adjustment in the Speciality Medicines Share Price.

The pattern is straightforward: the open and high were identical to the previous close, while the low marked the weakest point of the day so far. That places Speciality Medicines Share Price firmly in negative territory for the session, with SPML Share Price Live trading around the lower end of the range. For readers following Speciality Medicines Share Price Today, the market is clearly repricing the stock lower on the day, and the next step is to check whether the fundamental picture offers context for the move.

Speciality Medicines (SPML) Fundamental Analysis

Metric Value
Market Capitalisation Rs 165.13 crore
P/E Ratio 12.86x
P/B Ratio 2.35x
ROE 37.85%
ROCE 34.47%
EPS Rs 14.83
Book Value Per Share Rs 81.03
Dividend Yield 0%

Speciality Medicines (SPML) fundamental metrics show P/E 12.86x, P/B 2.35x, ROE 37.85%, ROCE 34.47%. These figures provide context only and are not a buy or sell signal.

Speciality Medicines has a market capitalisation of Rs 165.13 crore and falls in the Micro Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 12.86x, P/B at 2.35x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 37.85% and ROCE of 34.47%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 14.83, book value per share of Rs 81.03, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 22.64x, median ROE of 4.11%, median ROCE of 6.09%. Taken together, they outline the fundamentals rather than a view on the stock.

Sector and Industry Context

Metric Value
Sector Trading
Industry Trading
Benchmark Scope same industry
Company P/E Ratio 12.86x
Benchmark Median P/E 22.64x
Benchmark Average P/E 109.66x
Benchmark P/E Range 0.14x to 9,280.36x
Company P/B Ratio 2.35x
Benchmark Median P/B 1.37x
Benchmark Average P/B 2.74x
Company ROE 37.85%
Benchmark Median ROE 4.11%
Benchmark Average ROE 4.92%
Company ROCE 34.47%
Benchmark Median ROCE 6.09%
Benchmark Average ROCE 7.72%
Company Market Capitalisation Rs 165.13 crore
Benchmark Median Market Cap Rs 53.16 crore
Benchmark Average Market Cap Rs 1,576.69 crore

Speciality Medicines (SPML) operates in the Trading sector, within the Trading industry.

Speciality Medicines (SPML) has a P/E ratio of 12.86x, which is below the benchmark median of 22.64x, a difference of -43.2%. On its own, the P/E gap is a valuation reference point, not a trading call.

Speciality Medicines (SPML) has a ROE of 37.85%, which is above the benchmark median of 4.11%, a difference of +820.92%. Speciality Medicines (SPML) has a ROCE of 34.47%, which is above the benchmark median of 6.09%, a difference of +466.01%.

Track stocks among today's decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.

Peer Comparison

Company Symbol Market Cap (Cr) P/E P/B ROE (%) ROCE (%)
Adani Enterprises ADANIENT 3,71,461.48 47.19 3.72 15.07 13.3
Aegis Logistics AEGISLOG 51,244.25 38.79 7.35 20.71 19.76
ADITYA INFOTECH CPPLUS 49,776.12 102.08 13.86 25.68 29.48
Premier Energies PREMIERENE 41,400.38 24.16 8.46 42.6 33.72
Redington REDINGTON 31,763.5 17.83 2.86 13.6 18.96

Speciality Medicines (SPML) has a P/E ratio of 12.86x compared with the displayed peer median of 38.79x. This peer read is a relative benchmark rather than a trading signal. Its ROE of 37.85% compares with a peer median of 20.71% across the companies shown in the table. ROCE stood at 34.47% versus the displayed peer median of 19.76%, providing a capital-efficiency comparison. Speciality Medicines (SPML) has a market capitalisation of Rs 165.13 crore. All 5 peers shown have a larger market capitalisation.

Why Investors Are Watching Speciality Medicines

  • Speciality Medicines Share Price fell 10.85% to Rs 170, making today’s decline the most immediate focus.
  • SPML trades in the Micro Cap category with a market capitalisation of Rs 165.13 crore.
  • The company’s P/E of 12.86 is below the Trading industry median of 22.64.
  • ROE of 37.85% and ROCE of 34.47% stand well above sector medians.
  • Speciality Medicines Share Price News today is price-led, because no company-specific catalyst is established.

About Speciality Medicines

Speciality Medicines operates in the Trading sector and Trading industry. The company’s business profile, as reflected in the available company context, is linked to trading activity rather than a broad manufacturing or consumer franchise. Speciality Medicines Share Price therefore needs to be read alongside its role in a sector where valuation and capital efficiency can vary widely across listed peers.

Its market position today is that of a Micro Cap company with Rs 165.13 crore market capitalisation. That makes SPML smaller than many of the listed peers used for context, but the company’s return ratios show that Speciality Medicines Share Price is supported by strong profitability measures on the latest figures. For readers scanning Speciality Medicines Share News, the business profile and the market metrics together form the relevant backdrop.

Track Speciality Medicines Share Price on Univest

Use Speciality Medicines (SPML) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners and related market analysis.

You can track Speciality Medicines Share Price on Univest for live price updates, fundamental ratios, 52-week levels and market insights in one place. SPML Share Price Live tracking can help readers review price action, valuation, and sector context together. Univest also keeps Speciality Medicines Share Price Today connected to company fundamentals and peer comparisons.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).

Frequently Asked Questions

Why did Speciality Medicines Share Price fall today?

Ans. Speciality Medicines Share Price fell 10.85% to Rs 170 from Rs 190.7. According to Univest data, the price event is confirmed, but no company-specific catalyst is established, so the move is best read as price action first.

What is Speciality Medicines Share Price today?

Ans. Speciality Medicines Share Price was at Rs 170, down Rs 20.7 from the previous close of Rs 190.7. The stock traded between Rs 169.95 and Rs 190.7 during the day so far.

Is Speciality Medicines a Micro Cap stock?

Ans. Yes. Speciality Medicines Share Price is being discussed in the Micro Cap category, with market capitalisation of Rs 165.13 crore. That size context is useful when comparing SPML with larger Trading-sector peers.

What does Speciality Medicines Share Price valuation show?

Ans. Speciality Medicines Share Price is supported by a P/E ratio of 12.86 and a P/B ratio of 2.35. The P/E sits below the Trading industry median of 22.64, while the P/B is above the median of 1.37.

How strong are the profitability ratios for SPML?

Ans. SPML shows ROE of 37.85% and ROCE of 34.47%, both well above the Trading industry median and average. These numbers suggest strong capital efficiency relative to the wider sector benchmark.

What is the EPS and book value for Speciality Medicines Share Price?

Ans. EPS is Rs 14.83 and book value is Rs 81.03. EPS reflects earnings attributable to each share, while book value shows the accounting net worth behind each Speciality Medicines Share Price unit.

Does Speciality Medicines pay a dividend?

Ans. The latest figures show a dividend yield of 0% for Speciality Medicines Share Price. That means the current discussion is more centred on valuation and return ratios than on income yield.

How does SPML compare with Trading sector peers?

Ans. Speciality Medicines Share Price has a lower P/E than Adani Enterprises, Aegis Logistics, Aditya Infotech and Premier Energies, while its ROE is stronger than several of those peers. That is the key comparison point.

Should investors track Speciality Medicines Share Price on Univest?

Ans. Yes. Speciality Medicines Share Price can be tracked on Univest for live price updates, valuation ratios, 52-week levels and sector context. That helps keep SPML Stock News, fundamentals and price action in one view.



Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply